Login / Signup

Development of subtype-selective covalent ligands for the adenosine A 2B receptor by tuning the reactive group.

Bert L H BeerkensXuesong WangMaria AvgeropoulouLisa N AdistiaJacobus P D van VeldhovenWillem JespersRongfang LiuLaura H HeitmanAdriaan P IJzermanLaura H Heitman
Published in: RSC medicinal chemistry (2022)
Signalling through the adenosine receptors (ARs), in particular through the adenosine A 2B receptor (A 2B AR), has been shown to play a role in a variety of pathological conditions, ranging from immune disorders to cancer. Covalent ligands for the A 2B AR have the potential to irreversibly block the receptor, as well as inhibit all A 2B AR-induced signalling pathways. This will allow a thorough investigation of the pathophysiological role of the receptor. In this study, we synthesized and evaluated a set of potential covalent ligands for the A 2B AR. The ligands all contain a core scaffold consisting of a substituted xanthine, varying in type and orientation of electrophilic group (warhead). Here, we find that the right combination of these variables is necessary for a high affinity, irreversible mode of binding and selectivity towards the A 2B AR. Altogether, this is the case for sulfonyl fluoride 24 (LUF7982), a covalent ligand that allows for novel ways to interrogate the A 2B AR.
Keyphrases
  • binding protein
  • squamous cell carcinoma
  • protein kinase
  • drinking water
  • young adults
  • papillary thyroid
  • molecular docking
  • uric acid
  • endothelial cells